The Company has granted to affiliates of GPP the right to nominate two Board members to Abeona's Board of Directors, including a new Executive Chairman, due to GPP's considerable investment in the transaction.
Abeona Therapeutics Inc. announced today that the US Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to ABO-102
Abeona Therapeutics announced the FDA has granted Rare Pediatric Disease Designation for the ABO-202 program an AAV-based gene therapy for the treatment of CLN1 disease